Physician profile
Mark D Pennington
NPI 1720080476
$1,081.62
in general payments reported to CMS, 2019-2025
14 companies · $334 in 2025
The $334 reported for 2025 was less than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.01 · 2020: $23.33 · 2021: $79.12 · 2022: $55.93 · 2023: $300 · 2024: $225 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $859.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $280.15 | 2023-2025 | Sotyktu |
| Abbvie INC. | $227.64 | 2019-2025 | |
| Galderma Laboratories, L.P. | $225.50 | 2023-2025 | Nemluvio |
| Pfizer INC. | $65.33 | 2021-2025 | |
| Incyte Corporation | $50.39 | 2021-2023 | Opzelura |
| Janssen Biotech, INC. | $47.10 | 2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $45.69 | 2020-2023 | Ilumya |
| Amgen INC. | $33.61 | 2024 | Otezla |
| Genzyme Corporation | $28.85 | 2023 | |
| Novartis Pharmaceuticals Corporation | $20.00 | 2025 | |
| Arcutis Biotherapeutics, INC. | $19.08 | 2024 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.75 | 2019 | |
| Dermavant Sciences, INC. | $14.77 | 2024 | Vtama |
| Organon LLC | $4.76 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Pennington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.